- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
-
ESG profile
- Media
- Partners
- Contact Us
Press Releases
Dec
- Dr. Reddy's Laboratories announces the launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL) Single-dose Vial in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Deferasirox Film-Coated Tablets, in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Deferasirox Tablets for Oral Suspension, in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection 3.5 mg/vial for Intravenous use only in the U.S. Market
Nov
Oct
Sep
- Dr. Reddy’s announces the launch of over-the-counter, store-brand equivalent of Prevacid® 24HR Capsules (Lansoprazole Delayed-Release Capsules USP, 15 mg) in the U.S. Market
- Reddy's Laboratories announces the launch of Fosaprepitant for Injection in the U.S. Market
- Dr. Reddy's Laboratories Limited to present at the Morgan Stanley Annual Global Healthcare Conference
- Dr. Reddy's Laboratories announces the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR) in the U.S. Market
Aug
Jul
- Dr. Reddy's Laboratories announces the launch of Pregabalin Capsules in the U.S. Market
- Dr. Reddy’s Q1 FY20 Financial Results
- Dr. Reddy's Laboratories announces the launch of Ramelteon Tablets, in the U.S. Market
- Dr. Reddy’s Laboratories announces closure of the transaction to divest ZEMBRACE® SYMTOUCH® and TOSYMRATM to Upsher-Smith Laboratories, LLC
- Dr. Reddy’s announces the launch of over-the-counter, store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) in the U.S. Market
- Dr. Reddy’s announces the launch of the over-the-counter store brand equivalent of Mucinex® D Extended Release Tablets in two strengths in the U.S. Market
- Dr. Reddy's Laboratories announces first-to-market launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. Market
Jun
- Dr. Reddy's Laboratories announces the launch of Tobramycin Inhalation Solution, USP in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market
- Dr. Reddy’s Laboratories announces entering into a definitive agreement to sell its neurology branded products to Upsher-Smith Laboratories, LLC
- Dr. Reddy’s Laboratories announces entering into a definitive agreement to sell its neurology branded products to Upsher-Smith Laboratories, LLC
- Dr. Reddy's Laboratories Limited to present at the Goldman Sachs 40th Annual Global Healthcare Conference
- Dr. Reddy's Laboratories Limited through its wholly owned subsidiary, Dr. Reddy’s Laboratories SA, announces positive topline results from Phase 2b study of PPC-06 in patients with moderate to severe plaque psoriasis
- Dr. Reddy's Laboratories announces the re-launch of Zenatane® (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg in the U.S. Market
- Dr. Reddy's Laboratories announces filing of Annual Report on Form 20-F
May
- Dr. Reddy’s Q4 & FY19 Financial Results
- Dr. Reddy's Laboratories announces the launch of Daptomycin for Injection, 500mg/vial single-dose vial in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation) in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation) in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation) in the U.S. Market
Apr
Mar
Feb
Jan
- Dr. Reddy's Laboratories and its U.S. subsidiary, Promius Pharma, announce FDA approval for TOSYMRA™ (sumatriptan nasal spray) 10 mg, in the U.S. market
- Dr. Reddy's Laboratories announces the launch of Propofol Injectable Emulsion, USP in the U.S. Market
- Dr. Reddy's Laboratories Limited to present at the 37th Annual J.P. Morgan Healthcare Conference
